[The prognostic significance of plasma Epstein-Barr virus DNA in patients with diffuse large B cell lymphoma]

Zhonghua Nei Ke Za Zhi. 2017 Nov 1;56(11):839-841. doi: 10.3760/cma.j.issn.0578-1426.2017.11.012.
[Article in Chinese]

Abstract

To retrospectively analyze the prognostic significance of plasma Epstein-Barr virus (EBV) DNA in 122 patients with diffuse large B cell lymphoma (DLBCL). Plasma EBV DNA positivity was related to advanced disease stage (P=0.030), B symptoms (P=0.004) and elevated serum lactic dehydrogenase (LDH) (P=0.001). Furthermore, univariate analysis indicated that plasma EBV DNA level was associated with worse overall survival (OS) (HR=0.223, 95%CI 0.096-0.518, P<0.001) and worse progression free survival (PFS) (HR=4.417, 95%CI 1.911-10.208, P<0.001), whereas multivariate analysis showed plasma EBV DNA as a probable independent prognostic factor of clinical outcome(HR=0.409, 95%CI 0.166-1.008, P=0.052).

回顾性分析122例弥漫大B细胞淋巴瘤(DLBCL)临床资料,探讨血浆EB病毒(EBV)DNA阳性(≥1.0×10(3) copies/ml)与DLBCL预后的关系。结果显示,血浆EBV DNA阳性与Ann Arbor分期高(P=0.030)、有B症状(P=0.004)、LDH水平高(P=0.001)相关。单因素分析显示,血浆EBV DNA阳性是影响DLBCL患者总体生存(HR=0.223,95%CI 0.096~0.518, P<0.001)及无进展生存(HR=4.417,95%CI 1.911~10.208, P<0.001)的预后因素;多因素分析显示,血浆EBV DNA可能是DLBCL总体生存的独立预后因素(HR=0.409, 95%CI 0.166~1.008,P=0.052)。.

Keywords: Diffuse large B-cell lymphoma; Epstein-Barr virus; Lymphoma; Prognosis.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • DNA, Viral / blood*
  • Disease-Free Survival
  • Epstein-Barr Virus Infections / complications*
  • Female
  • Herpesvirus 4, Human / genetics*
  • Herpesvirus 4, Human / isolation & purification
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Lymphoma, Large B-Cell, Diffuse / virology*
  • Male
  • Prognosis
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction
  • Treatment Outcome

Substances

  • DNA, Viral